Document is current
Any future updates will be listed below
-
Authors
Danciu, Oana C. http://orcid.org/0000-0003-4487-9136
Holdhoff, Matthias
Peterson, Richard A.
Fischer, James H.
Liu, Li C.
Wang, Heng
Venepalli, Neeta K.
Chowdhery, Rozina
Nicholas, M. Kelly
Russell, Meredith J.
Fan, Timothy M.
Hergenrother, Paul J.
Tarasow, Theodore M.
Dudek, Arkadiusz Z.
- License Information
-
More Information
Article History
Received: 14 April 2022
Revised: 18 November 2022
Accepted: 22 November 2022
First Online: 5 December 2022
Competing interests
: PJH serves as Chief Scientific Officer and has equity in Vanquish Oncology, Inc. TMT serves as Chief Executive Officer and has equity in Vanquish Oncology, Inc. TMF serves as VP Preclinical Development and has equity in Vanquish Oncology, Inc. AZD reports research funding from Eli Lilly. AZD served as Chief Medical Officer for Vanquish Oncology, Inc. AZD serves as Chief Executive Officer for TTC Oncology, LLC, and Chief Medical Officer for IGF Oncology. All other authors declare no competing interests.
: The study was conducted according to International Conference on Harmonisation of Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The protocol was approved by the Institutional Review Board/Ethics Committee at each study location. All patients provided written informed consent before enrolment.
: Not applicable.
